Daniel S. Pilch

Prof. Daniel S. Pilch

Department of Pharmacology, Rutgers Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854-5635, USA
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
INIgor Nudelman
Igor Nudelman
ARAnnie Rebibo-Sabbah
Annie Rebibo-Sabbah
MCMarina Cherniavsky
Marina Cherniavsky
VBValery Belakhov
Valery Belakhov
MHMariana Hainrichson
Mariana Hainrichson
TBTimor Baasov
Timor Baasov

23 July 1996 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
Natasa Poklar UlrihNatasa Poklar Ulrih
Natasa Poklar Ulrih
Daniel S. PilchDaniel S. Pilch
Daniel S. Pilch
SLS J Lippard
S J Lippard
ERE A Redding
E A Redding
SDS U Dunham
S U Dunham
KBK J Breslauer
K J Breslauer
Cis-Diamminedichloroplatinum(II) (cisplatin) is a widely used anticancer drug that binds to and crosslinks DNA. The major DNA adduct of the drug results from coordination of two adjacent guanine bases to platinum to form the intrastrand crosslink cis-[Pt(NH3)2[d(GpG)-N7(1), -N7(2)]] (cis-Pt-GG). In the present study, spectroscopic and calorimetric techniques were employed to characterize the influence of this crosslink on the conformation, thermal stability, and energetics of a site-specifically platinated 20-mer DNA duplex. CD spectroscopic and thermal denaturation data revealed that the crosslink alters the structure of the host duplex, consistent with a shift from a B-like to an A-like conformation; lowers its thermal stability by approximately 9 degrees C; and reduces its thermodynamic stability by 6.3 kcal/mol at 25 degrees C, most of which is enthalpic in origin; but it does not alter the two-state melting behavior exhibited by the parent, unmodified duplex, despite the significant crosslink-induced changes noted above. The energetic consequences of the cis-Pt-GG crosslink are discussed in relation to the structural perturbations it induces in DNA and to how these crosslink-induced perturbations might modulate protein binding.

1 September 2013 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
APAjit K. Parhi
Ajit K. Parhi
YZYongzheng Zhang
Yongzheng Zhang
KSKurt W. Saionz
Kurt W. Saionz
PPPadmanava Pradhan
Padmanava Pradhan
MKMalvika Kaul
Malvika Kaul
ELEdmond J. LaVoie
Edmond J. LaVoie


25 June 1991 in Biochemistry
Verified
Journal Article
Closed access
Daniel S. PilchDaniel S. Pilch
Daniel S. Pilch
CLCorey Levenson
Corey Levenson
RSRichard H. Shafer
Richard H. Shafer

1 August 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
MKMalvika Kaul
Malvika Kaul
LMLilly Mark
Lilly Mark
YZYongzheng Zhang
Yongzheng Zhang
APAjit K. Parhi
Ajit K. Parhi
YLYi Lisa Lyu
Yi Lisa Lyu
Daniel S. PilchDaniel S. Pilch
Daniel S. Pilch
The clinical development of FtsZ-targeting benzamide compounds like PC190723 has been limited by poor drug-like and pharmacokinetic properties. Development of prodrugs of PC190723 (e.g., TXY541) resulted in enhanced pharmaceutical properties, which, in turn, led to improved intravenous efficacy as well as the first demonstration of oral efficacy in vivo against both methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA). Despite being efficacious in vivo , TXY541 still suffered from suboptimal pharmacokinetics and the requirement of high efficacious doses. We describe here the design of a new prodrug (TXA709) in which the Cl group on the pyridyl ring has been replaced with a CF 3 functionality that is resistant to metabolic attack. As a result of this enhanced metabolic stability, the product of the TXA709 prodrug (TXA707) is associated with improved pharmacokinetic properties (a 6.5-fold-longer half-life and a 3-fold-greater oral bioavailability) and superior in vivo antistaphylococcal efficacy relative to PC190723. We validate FtsZ as the antibacterial target of TXA707 and demonstrate that the compound retains potent bactericidal activity against S. aureus strains resistant to the current standard-of-care drugs vancomycin, daptomycin, and linezolid. These collective properties, coupled with minimal observed toxicity to mammalian cells, establish the prodrug TXA709 as an antistaphylococcal agent worthy of clinical development.